“This is the beginning of an exploration and an identification,” says Steven A. Kaplan, MD.
In this video, Steven A. Kaplan, MD, discusses his patient selection process for BPH treatments and shares the take-home message of the study, “UroLift PUL compared to Rezum, TURP and GreenLight PVP: US Medicare and commercial claims analysis reveals lowest complications for PUL and highest retreatment for Rezum,” presented at the 2021 American Urological Association annual meeting. Kaplan is a professor of urology at the Icahn School of Medicine and director of the Men’s Wellness Program at Mount Sinai, New York, New York.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.